Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗,或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
City of Hope Medical center, Duarte, California, United States
University of Michigan, Ann Arbor, Michigan, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Oulu University Hospital, Oulu, Finland
Oslo University Hospital, Oslo, Norway
Uppsla Academic Hospital, Uppsala, Sweden
OSF Saint Francis Medical Center, Peoria, Illinois, United States
Illinois CancerCare-Peru, Peru, Illinois, United States
Valley Radiation Oncology, Peru, Illinois, United States
University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
David Geffen School of Medicin /ID# 200015, Los Angeles, California, United States
The Ohio State University /ID# 200668, Columbus, Ohio, United States
Gold coast University Hospital /ID# 202759, SouthPort, Queensland, Australia
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
M D Anderson Cancer Center, Houston, Texas, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
Norton Cancer Institute, Louisville, Kentucky, United States
John Theurer Cancer Center, Hackensack, New Jersey, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.